Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
Status:
Recruiting
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
This study is a multi-institution, open-label, Phase 1b/2 clinical trial evaluating the
toxicity and efficacy of canakinumab in combination with darbepoetin alfa in patients with
lower-risk MDS who have failed prior treatment with an Erythropoietin Stimulating Agent (ESA)
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute